Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

NCT04959175 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

320

Enrollment

NIH

Sponsor class

Conditions

Hematologic Neoplasms

Interventions

DRUG: Mycophenolate Mofetil
PROCEDURE: Allogeneic HSCT
DRUG: Fludarabine
DRUG: Sirolimus
DRUG: Filgrastim
DRUG: Cyclophosphamide
DRUG: Mesna
PROCEDURE: Total Body Irradiation (TBI)

Sponsor

National Cancer Institute (NCI)